Dupont Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Dupont Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-230,491	Closed	-$1.6M	–	767
2022 Q4	$1.6M	Sell	230,491 -33,433	-13%	-$191K	0.08%	196
2022 Q3	$1.41M	Buy	263,924 +105,893	+67%	+$635K	0.08%	272
2022 Q2	$631K	Hold	158,031	–	–	0.03%	624
2022 Q1	$702K	Sell	158,031 -4,103	-3%	-$16.3K	0.03%	634
2021 Q4	$649K	Buy	162,134 +98,348	+154%	+$750K	0.02%	705
2021 Q3	$560K	Buy	+63,786	New	+$585K	0.02%	809

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dupont Capital Management's ALDX Position: Q1 2023 in Review

Dupont Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2023, closing a stake of 230,491 shares — an estimated $1.6M sold.

Dupont Capital Management first reported a position in ALDX in Q3 2021 and held it in 6 quarters. The position peaked at $1.6M in Q4 2022. 108 funds tracked by Wall St. Rank hold ALDX as of Q1 2023.

Dupont Capital Management reported no remaining Aldeyra Therapeutics position as of Q1 2023 after selling out during the quarter.
Dupont Capital Management sold 230,491 Aldeyra Therapeutics shares in Q1 2023, an estimated $1.6M.
Dupont Capital Management first reported a position in Aldeyra Therapeutics in Q3 2021 and held it in 6 quarters.
Dupont Capital Management's Aldeyra Therapeutics position peaked at $1.6M in Q4 2022.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.